2016
DOI: 10.1016/j.ygeno.2016.04.001
|View full text |Cite
|
Sign up to set email alerts
|

RNA-seq analysis of hippocampal tissues reveals novel candidate genes for drug refractory epilepsy in patients with MTLE-HS

Abstract: Array-based profiling studies have shown implication of aberrant gene expression patterns in epileptogenesis. We have performed transcriptome analysis of hippocampal tissues resected from patients with MTLE-HS using RNAseq approach. Healthy tissues from tumour margins obtained during tumour surgeries were used as non-epileptic controls. RNA sequencing was performed using standard protocols on Illumina HiSeq 2500 platform. Differential gene expression analysis of the RNAseq data revealed 56 significantly regula… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
54
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 108 publications
(68 citation statements)
references
References 74 publications
3
54
0
Order By: Relevance
“…Here, we report a male patient with intellectual disability and myoclonic epilepsy beginning during infancy who was found to have a de novo heterozygous frameshift mutation in CSNK2B . The involvement of CSNK2B in epileptogenicity is supported by the results of a previous RNA‐seq analysis of hippocampal tissues in a cohort of patients with mesial temporal lobe epilepsy‐hippocampal sclerosis, which showed the downregulation of CSNK2B expression (Dixit et al., ). Our present mutation analysis data agreed with this semiquantitative expression analysis data of hippocampal tissues from a cohort of patients with refractory epilepsy.…”
mentioning
confidence: 69%
“…Here, we report a male patient with intellectual disability and myoclonic epilepsy beginning during infancy who was found to have a de novo heterozygous frameshift mutation in CSNK2B . The involvement of CSNK2B in epileptogenicity is supported by the results of a previous RNA‐seq analysis of hippocampal tissues in a cohort of patients with mesial temporal lobe epilepsy‐hippocampal sclerosis, which showed the downregulation of CSNK2B expression (Dixit et al., ). Our present mutation analysis data agreed with this semiquantitative expression analysis data of hippocampal tissues from a cohort of patients with refractory epilepsy.…”
mentioning
confidence: 69%
“…To ensure this result was not due to the threshold we used when identifying tissue-specific TFs, we selected the ten transcription factors with the highest and lowest expression enrichment in this brain-tissue subregion (see Supplemental Material and Methods) and performed a detailed investigation of their GSEA profiles ( Figure 4B). NEUROD2 and SP8 were the top tissue-specific transcription factors with brain-function associated targeting profiles; these TFs play important roles in brain function [31][32][33]. In addition, four of the highly non-tissuespecific transcription factors (based on expression)-GRHL1, KLF15, PAX3, and TET1-have positive enrichment for targeting genes with relevant brain functions.…”
Section: Evaluating Tissue-specific Regulation Of Biological Processesmentioning
confidence: 99%
“…Using RNA-seq analysis of the hippocampal tissue resected from patients with HS, we have previously identified hubs of genes linked to synaptic transmission and neuronal network modulation 18 . We reported significant alterations in the expression levels of transporters, receptors and molecules involved in calcium signalling 18 . However, in that study we could not detect mRNA level alterations of NR2A levels in the RNAseq analysis, which could be attributed to the small sample size.…”
Section: Discussionmentioning
confidence: 99%
“…qPCR was performed in an independent set of 10 patients (both hippocampal and ATL) and 10 non-seizure control samples. RNA was extracted, purified and analyzed for purity by calculating the RIN values as previously described 18 . Purified RNA was reverse transcribed using high capacity cDNA reverse transcription kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer protocol.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation